Unknown

Dataset Information

0

Local angiotensin II contributes to tumor resistance to checkpoint immunotherapy.


ABSTRACT:

Background

Current checkpoint immunotherapy has shown potential to control cancer by restoring or activating the immune system. Nevertheless, multiple mechanisms are involved in immunotherapy resistance which limits the clinical benefit of checkpoint inhibitors. An immunosuppressive microenvironment is an important factor mediating the original resistance of tumors to immunotherapy. A previous report by our group has demonstrated that local angiotensin II (AngII) predominantly exists in a tumor hypoxic microenvironment where hypoxic tumour cells produced AngII by a hypoxia-lactate-chymase-dependent mechanism.

Results

Here, using 4T1 and CT26 syngeneic mouse tumor models, we found that local AngII in the tumor microenvironment was involved in immune escape of tumour cells and an AngII signaling blockage sensitized tumours to checkpoint immunotherapy. Furthermore, an AngII signaling blockage reversed the tumor immunosuppressive microenvironment, and inhibition of angiotensinogen (AGT, a precursor of AngII) expression strongly triggered an immune-activating cytokine profile in hypoxic mouse cancer cells. More importantly, AGT silencing combined with a checkpoint blockage generated an abscopal effect in resistant tumors.

Conclusion

Our study demonstrated an important role of local AngII in the formation of a tumor immunosuppressive microenvironment and its blockage may enhance tumor sensitivity to checkpoint immunotherapy. The combination of an AngII signaling blocker and an immune-checkpoint blockage could be a promising strategy to improve tumors responses to current checkpoint immunotherapy.

SUBMITTER: Xie G 

PROVIDER: S-EPMC6134794 | biostudies-literature | 2018 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

Local angiotensin II contributes to tumor resistance to checkpoint immunotherapy.

Xie Guozhu G   Cheng Tan T   Lin Jie J   Zhang Lanfang L   Zheng Jieling J   Liu Ying Y   Xie Guobo G   Wang Baiyao B   Yuan Yawei Y  

Journal for immunotherapy of cancer 20180912 1


<h4>Background</h4>Current checkpoint immunotherapy has shown potential to control cancer by restoring or activating the immune system. Nevertheless, multiple mechanisms are involved in immunotherapy resistance which limits the clinical benefit of checkpoint inhibitors. An immunosuppressive microenvironment is an important factor mediating the original resistance of tumors to immunotherapy. A previous report by our group has demonstrated that local angiotensin II (AngII) predominantly exists in  ...[more]

Similar Datasets

| S-EPMC5406290 | biostudies-literature
| S-EPMC4339088 | biostudies-literature
| S-EPMC4106918 | biostudies-literature
2019-10-01 | GSE98827 | GEO
| S-EPMC7047187 | biostudies-literature
| S-EPMC5522228 | biostudies-other
| S-EPMC7669613 | biostudies-literature
| S-EPMC10110722 | biostudies-literature
| S-EPMC3392235 | biostudies-literature
| S-EPMC7192950 | biostudies-literature